Literature DB >> 14636895

Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells.

Anna-Louise M Cook1, John M Haynes.   

Abstract

This study investigates the effect of protein kinase G (PKG) activation upon proliferation of human cultured prostatic stromal cells. The PKG II activator (8-pCPT-cGMP; IC50 of 113+/-42 nM) and the phosphodiesterase inhibitor, zaprinast (up to 50 microM), but not the PKG I isoform activators (APT-cGMP and PET-cGMP), reduced foetal calf serum-stimulated proliferation. The effect of 8-pCPT-cGMP (30 microM) was blocked by Rp-8-Br-cGMPS (5 microM) and Rp-8-pCPT-cGMP (5 microM), but not Rp-cAMPS (5 microM). 8-pCPT-cGMP (30 microM) and zaprinast (50 microM), but not PET-cGMP (30 microM), caused a significant increase in atypical nuclei and an increase in annexin-V staining. These data indicate that activation of PKG II induces apoptosis of human cultured prostatic stromal cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14636895     DOI: 10.1016/s0898-6568(03)00134-7

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  17 in total

1.  Phosphodiesterase sequence variants may predispose to prostate cancer.

Authors:  Rodrigo B de Alexandre; Anelia D Horvath; Eva Szarek; Allison D Manning; Leticia F Leal; Fabio Kardauke; Jonathan A Epstein; Dirce M Carraro; Fernando A Soares; Tatiyana V Apanasovich; Constantine A Stratakis; Fabio R Faucz
Journal:  Endocr Relat Cancer       Date:  2015-05-15       Impact factor: 5.678

2.  Endogenous cGMP-dependent protein kinase reverses EGF-induced MAPK/ERK signal transduction through phosphorylation of VASP at Ser239.

Authors:  Yan Tao; Yin-Jie Gu; Zhi-Hong Cao; Xiu-Juan Bian; Ting Lan; Jian-Rong Sang; Lu Jiang; Ying Wang; Hai Qian; Yong-Chang Chen
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

Review 3.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Type II cyclic guanosine monophosphate-dependent protein kinase inhibits epidermal growth factor receptor activation in different cancer cell lines.

Authors:  L U Jiang; Min Wu; Yan Wu; Ting Lan; Ying Wang; Hai Qian; Yongchang Chen
Journal:  Oncol Lett       Date:  2015-03-23       Impact factor: 2.967

5.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

6.  The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects.

Authors:  Amit N Keswani; Kelly J Peyton; William Durante; Andrew I Schafer; David A Tulis
Journal:  J Cardiovasc Pharmacol Ther       Date:  2009-04-02       Impact factor: 2.457

7.  Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia.

Authors:  Esref O Guven; Mevlana D Balbay; Kilciler Mete; Ege C Serefoglu
Journal:  Int Urol Nephrol       Date:  2008-07-22       Impact factor: 2.370

8.  Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines.

Authors:  F J Swartling; M Ferletta; M Kastemar; W A Weiss; B Westermark
Journal:  Oncogene       Date:  2009-06-22       Impact factor: 9.867

9.  Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells.

Authors:  Lu Jiang; Yongchang Chen; Jianrong Sang; Yueying Li; Ting Lan; Ying Wang; Yan Tao; Hai Qian
Journal:  Biomed Rep       Date:  2013-03-21

10.  Expression of cGMP-dependent protein kinase, PKGIα, PKGIβ, and PKGII in malignant and benign breast tumors.

Authors:  Fatemeh Karami-Tehrani; Faranak Fallahian; Morteza Atri
Journal:  Tumour Biol       Date:  2012-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.